TrialBMC pediatrics2024

Assessment of the safety and gut microbiota modulation ability of an infant formula containing Bifidobacterium animalis ssp. lactis CP-9 or Lactobacillus salivarius AP-32 and the effects of the formula on infant growth outcomes: insights from a four-month clinical study in infants under two months old.

Shang-Po Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.